On Friday, Royal Dutch Shell plc (ADR) (NYSE:RDS.A)’s shares declined -3.88% to $49.52.
Royal Dutch Shell plc (RDS-A) declares that application has been made to the UK Listing Authority and the London Stock Exchange for 23,865,981 A ordinary shares of Eur 0.07 each in the capital of Shell to be admitted to the Official List of the United Kingdom Listing Authority and to be traded on the main market of the London Stock Exchange. Application will also be made to Euronext Amsterdam for the Shares to be admitted to trading on Euronext Amsterdam.
The Shares are to be issued as a scrip dividend alternative to receiving a cash dividend in respect of the second quarter 2015 interim dividend and dealings are predictable to commence on September 21, 2015.
Royal Dutch Shell plc operates as an independent oil and gas company worldwide. It operates through Upstream and Downstream segments. The company explores for and extracts crude oil, natural gas, and natural gas liquids.
Endo International, (NASDAQ:ENDP)’s shares gained 1.15% to $81.92.
Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), and BioDelivery Sciences International, Inc. (BDSI) presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA®) drug delivery technology. The findings, presented in a poster session at PAINWeek 2015 in Las Vegas , showed that study participants receiving around-the-clock therapy with an opioid full agonist (morphine or oxycodone) could be switched to buprenorphine HCl buccal film, at about half the full agonist dose, without increasing the risk of experiencing opioid withdrawal or a loss of pain relief. These findings also will be presented later this month at the 26th Annual Meeting of the American Academy of Pain Administration in National Harbor, MD.
Buprenorphine HCl buccal film is being developed under the proprietary name BELBUCA™ (buprenorphine HCl) buccal film and is presently under review by the U.S. Food and Drug Administration (FDA) for use in patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The PDUFA action date is in October 2015.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals.
At the end of Friday’s trade, Apartment Investment and Administration Co (NYSE:AIV)‘s shares decreased -0.38% to $36.27.
Apartment Investment and Administration Company (AIV) declared that its Board of Directors declared dividends on shares of its Class A and Z Cumulative Preferred Stock. Dividend information is as follows:
Dividends on shares of Class A and Z Cumulative Preferred Stock are payable on October 15, 2015, to shareholders of record on October 1, 2015.
Apartment Investment and Administration Company is a real estate investment trust. The firm engages in the acquisition, ownership, administration, and redevelopment of apartment properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
